Tumor-Targeted Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-oncology Therapeutics

Time: 4:20 pm
day: Day Two


• Introducing Bolt’s ISAC technology platform as the next evolution in immune-oncology and antibody drug conjugates
• Showcasing key features of ISAC technology and mechanism of action
• Demonstrating the promise of the ISAC platform and Bolt’s approach to develop this new class